What Type of Evidence - Alternative trial designs for rare cancers

What Type of Evidence - Alternative trial designs for rare cancers

What Type of Evidence - Alternative trial designs for rare cancers (#93)

Martin Stockler ¹

NHMRC Clinical Trials Centre, Stanmore, NSW, Australia

Determining the optimal management of rare cancers is challenging. This presentation will focus on special aspects of the design, conduct and analysis of clinical research studies in rare cancers. Key strategies will be illustrated with recent examples, particularly simplifying the trial question, streamlining trial processes, and striving for economies of scale by increasing the numbers of potential participants, investigators and sites.

#COSA2015

Authors contributing to this presentation.

Stockler, M

Martin Stockler is co-director of Oncology at the NHMRC Clinical Trials Centre and its Clinical Lead for ANZUP. He is Professor of Oncology and Clinical Epidemiology, University of Sydney, and consultant medical oncologist at the Concord Cancer Centre and Chris O’Brien Lifehouse RPA. His research has focused on improving survival and quality of life for people with cancer, particularly of the prostate, testis, kidney and breast. Special interests include: the design, execution, analysis and synthesis of cancer clinical trials; quality of life and preferences as outcome measures in clinical trials; evidence-based medicine in clinical practice and medical education; patient–doctor communication; and, the management of genitourinary, breast and advanced cancers.

What Type of Evidence - Alternative trial designs for rare cancers (#93)

Add notes

Stockler, M

Login